NCT05237037

Assessment of Sleep Quality in Cannabinoid Therapy

Assessment of Sleep Quality in Patients Utilizing Cannabinoid Therapy

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 34 (estimated)
• Sponsor: Cerebra Medical · Industry
• Sex: All
• Age: 40 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The current study aims to assess the impact of starting cannabinoid therapy on sleep quality for individuals with sleep disturbance.

Detailed description

After the initial signing of the consent form, they will complete a battery of baseline questionnaires online on sleep, including the Sleep Regularity Questionnaire, Epworth Sleepiness Scale, Insomnia Severity Index, and the Depression, Anxiety, Stress Scale (DASS-21). That night, before beginning active treatment, participants will be monitored using Cerebra's Level 2 plus ECG system (the Prodigy). After 6 weeks of active treatment, participants will again complete a night of Level 2 plus ECG recording using the Prodigy, evening, and morning questionnaires, and will repeat baseline sleep questionnaires.

Conditions

• Poor Sleep Quality

Timeline

• Start date: 2022-08-22
• Primary completion: 2023-08-01
• Completion: 2023-08-01
• First posted: 2022-02-11
• Last updated: 2023-02-08

Locations

1 site across 1 country: Canada